Vaxxinity, Inc. (VAXX) Cash Flow Statement
Where VAXX’s cash came from and went, 2023
December 31, 2023 · U.S. dollars- Cash from operations
- −$57.2M
- Capital expenditures
- $803,000
- Free cash flow
- −$58.0M
- Returned to shareholders
- —
- Change in cash
- −$29.5M cash at year-end $5.0M
Drawn to scale: where the cash came from and how it was used. Hover for values.
VAXX operating cash flow, capex and free cash flow
VAXX cash flow trends, 2019–2023
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Operating cash flow | −$12.3M2019 | −$57.2M2023 | — | |
| Capital expenditures | $1.5M2019 | $803,0002023 | −14.1%/yr | |
| Free cash flow | −$12.3M2019 | −$58.0M2023 | — | |
| Free cash flow margin | −6,353.1%2020 | −124,709.1%2021 | −118,355.9 pts | |
| Stock-based compensation | $1.2M2019 | $7,5082023 | −72.0%/yr | |
| Share buybacks (net) | $02019 | $02022 | — | |
| Capex / revenue | 265.2%2020 | 1,997.0%2021 | +1,731.8 pts |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
VAXX cash flow by activity
VAXX net income vs operating cash flow
Operating cash flow above net income usually means earnings are backed by cash (depreciation and stock-based pay are non-cash expenses).
VAXX cash flow statement
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Operating activities | |||||
| Net income | −$56.9M | −$75.2M | −$137.2M | −$40.0M | −$14.2M |
| Depreciation & amortization | $2.2M | $1.7M | $1.1M | $717,000 | $107,000 |
| Stock-based compensation | $7,508 | $8.7M | $30.4M | $1.0M | $1.2M |
| Change in working capital | −$8.5M | $9.8M | $12.9M | −$2.8M | $157,000 |
| Other non-cash items | $6.0M | −$926,000 | $11.8M | $7.1M | $462,000 |
| Cash from operating activities | −$57.2M | −$55.9M | −$81.0M | −$33.9M | −$12.3M |
| Investing activities | |||||
| Capital expenditures | −$803,000 | −$1.9M | −$1.3M | −$1.5M | −$1.5M |
| Investments (net) | $56.5M | −$54.4M | −$1.3M | −$1.5M | −$52.5M |
| Acquisitions & other investing | −$26.8M | $1.9M | $1.3M | $1.5M | $52.5M |
| Cash from investing activities | $28.8M | −$54.4M | −$1.3M | −$1.5M | −$1.5M |
| Financing activities | |||||
| Dividends paid | — | — | — | −$59.8M | — |
| Share repurchases & issuance (net) | — | $263,000 | $59.9M | −$41,000 | $0 |
| Net borrowing (repayment) | −$1.6M | −$430,000 | −$814,000 | $6.6M | $11.1M |
| Shares issued | $0 | $71.1M | $193.9M | $20.4M | $0 |
| Other financing | $454,000 | −$71.1M | −$56.7M | $98.9M | $17,000 |
| Cash from financing activities | −$1.1M | −$167,000 | $196.2M | $66.1M | $11.1M |
| Summary | |||||
| Net change in cash | −$29.5M | −$110.5M | $113.9M | $30.7M | −$1.1M |
| Cash at end of period | $5.0M | $34.6M | $145.1M | $31.2M | $476,000 |
| Free cash flow | −$58.0M | −$57.8M | −$82.3M | −$35.4M | −$12.3M |
| Free cash flow margin | — | — | −124,709.1% | −6,353.1% | — |
| Capex / revenue | — | — | 1,997.0% | 265.2% | — |
| Mar '24 | Dec '23 | Sep '23 | Jun '23 | Mar '23 | Dec '22 | Sep '22 | Jun '22 | Mar '22 | Dec '21 | Sep '21 | Jun '21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||||
| Net income | −$11.4M | −$11.4M | −$13.1M | −$14.0M | −$18.4M | −$20.5M | −$19.3M | −$17.3M | −$18.3M | −$48.2M | −$30.4M | −$26.6M |
| Depreciation & amortization | $456,000 | $456,000 | $666,000 | $526,000 | $586,000 | $540,000 | $419,000 | $392,000 | $333,000 | $174,000 | $363,000 | $283,000 |
| Stock-based compensation | $1,081 | $1,081 | $1.8M | $2.4M | $2.2M | $2.4M | $2.4M | $1.8M | $2.2M | $24.8M | $1.5M | $699,000 |
| Change in working capital | −$1.7M | −$1.7M | −$2.1M | −$687,000 | −$4.0M | $3.6M | $5.5M | $4.5M | −$3.8M | $9.0M | $7.5M | $7.8M |
| Other non-cash items | $759,919 | $759,919 | −$337,000 | −$453,000 | −$393,000 | −$544,000 | −$409,000 | $13,000 | $14,000 | $273,000 | $10,000 | $30,000 |
| Cash from operating activities | −$11.8M | −$11.8M | −$13.2M | −$12.2M | −$20.1M | −$14.5M | −$11.4M | −$10.5M | −$19.5M | −$14.0M | −$21.1M | −$17.7M |
| Investing activities | ||||||||||||
| Capital expenditures | −$414,000 | −$414,000 | −$127,000 | −$90,000 | −$172,000 | −$292,000 | −$322,000 | −$539,000 | −$713,000 | −$1.3M | −$50,000 | −$50,000 |
| Investments (net) | — | −$407,000 | −$6.1M | $26.6M | $8.7M | $27.2M | −$80.3M | −$539,000 | −$713,000 | −$1.3M | −$50,000 | $0 |
| Acquisitions & other investing | $7,000 | $414,000 | $127,000 | $90,000 | $172,000 | $292,000 | $322,000 | $539,000 | $713,000 | $1.3M | $50,000 | $0 |
| Cash from investing activities | −$407,000 | −$407,000 | −$6.1M | $26.6M | $8.7M | $27.2M | −$80.3M | −$539,000 | −$713,000 | −$1.3M | −$50,000 | −$50,000 |
| Financing activities | ||||||||||||
| Share repurchases & issuance (net) | — | — | — | $393,000 | $4,000 | $1,000 | $29,000 | $112,000 | $121,000 | — | — | — |
| Net borrowing (repayment) | — | — | — | −$268,000 | −$577,000 | −$110,000 | −$107,000 | −$106,000 | −$107,000 | −$318,000 | −$357,000 | −$357,000 |
| Shares issued | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $71.1M | $52,000 | $79.4M |
| Other financing | −$313,000 | −$313,000 | −$379,000 | $1,000 | −$1,000 | $0 | $0 | $0 | $0 | $100,000 | −$44,000 | $371,000 |
| Cash from financing activities | −$313,000 | −$313,000 | −$379,000 | $126,000 | −$574,000 | −$109,000 | −$78,000 | $6,000 | $14,000 | $70.9M | −$349,000 | $79.4M |
| Summary | ||||||||||||
| Net change in cash | −$12.6M | −$12.6M | −$19.7M | $14.6M | −$11.9M | $12.6M | −$91.8M | −$11.1M | −$20.2M | $55.6M | −$21.5M | $61.7M |
| Cash at end of period | $5.0M | $5.0M | $17.6M | $37.3M | $22.7M | $34.6M | $21.9M | $113.8M | $124.8M | $145.1M | $89.4M | $110.9M |
| Free cash flow | −$12.3M | −$12.3M | −$13.3M | −$12.2M | −$20.2M | −$14.8M | −$11.7M | −$11.1M | −$20.2M | −$15.2M | −$21.1M | −$17.7M |
| Free cash flow margin | — | — | — | — | — | — | — | — | — | — | −42,248.0% | — |
| Capex / revenue | — | — | — | — | — | — | — | — | — | — | 100.0% | — |
Negative numbers are cash paid out. Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported; data from EODHD.
VAXX cash generation
In fiscal 2023 (ended December 31, 2023), Vaxxinity generated -$57.2 million of cash from operations and spent $0.8 million on capital expenditures, leaving free cash flow of -$58.0 million. Cash and equivalents fell by $29.5 million over the year.
Related: VAXX income statement, VAXX balance sheet. See the VAXX stock overview for the latest quote and news.
VAXX cash flow FAQ
What is Vaxxinity's free cash flow?
Vaxxinity's free cash flow was -$58.0 million in fiscal 2023: -$57.2 million of operating cash flow minus $0.8 million of capital expenditures It was -$57.8 million a year earlier..
How much cash does Vaxxinity generate from operations?
Vaxxinity generated -$57.2 million of cash from operating activities in fiscal 2023.
How much does Vaxxinity spend on capital expenditures?
Vaxxinity spent $0.8 million on capital expenditures in fiscal 2023, compared with $1.9 million the year before.